Sanofi Net Change in Investments - Total 2010-2025 | SNY
Sanofi annual/quarterly net change in investments - total history and growth rate from 2010 to 2025. Net change in investments - total can be defined as the total change in long term and short term investments
- Sanofi net change in investments - total for the quarter ending March 31, 2025 was $0M, a 0% increase year-over-year.
- Sanofi net change in investments - total for the twelve months ending March 31, 2025 was $-4.985B, a 28.99% decline year-over-year.
- Sanofi annual net change in investments - total for 2024 was $-2.731B, a 36.31% decline from 2023.
- Sanofi annual net change in investments - total for 2023 was $-4.288B, a 202.37% increase from 2022.
- Sanofi annual net change in investments - total for 2022 was $-1.418B, a 79.93% decline from 2021.
Sanofi Annual Net Change in Investments - Total
(Millions of US $) |
| 2024 |
$-2,731 |
| 2023 |
$-4,288 |
| 2022 |
$-1,418 |
| 2021 |
$-7,067 |
| 2020 |
$-6,381 |
| 2019 |
$-694 |
| 2018 |
$-15,414 |
| 2017 |
$-1,667 |
| 2016 |
$-705 |
| 2015 |
$-500 |
| 2014 |
$-2,887 |
| 2013 |
$-377 |
| 2012 |
$-428 |
| 2011 |
$-18,928 |
| 2010 |
$-2,301 |
| 2009 |
$-7,758 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$120.637B |
$44.458B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
